ELEKTA CHOSEN TO DELIVER ADVANCED 3-D BRAIN MAPPING TECHNOLOGY AS PART OF COLLABORATION WITH LEADING FRENCH BRAIN IMAGING FACILITY

ELEKTA CHOSEN TO DELIVER ADVANCED 3-D BRAIN MAPPING TECHNOLOGY AS PART OF
COLLABORATION WITH LEADING FRENCH BRAIN IMAGING FACILITY

Press Release 
Stockholm, Sweden, February 22, 2008

Elekta has signed a contract to deliver Elekta Neuromag®, the world-leading
equipment for non-invasive registration of nerve cell activity using
magnetoencephalography (MEG) technology to the new CEA facility - NeuroSpin in
Saclay, France, one of the largest research sites for brain imaging in Europe.

The delivery of Elekta Neuromag is part of a collaboration contract signed
between three parties: Le Commissariat à l'Energie Atomique (CEA), L'Institut
National de la Santé et de la Recherche Médicale (INSERM) both French
state-owned research entities with scientific, technical and industrial
activity, and Elekta Neuromag Oy, part of the Elekta Group.

The MEG system will be installed during spring of 2008 at the new CEA facility -
called NeuroSpin - in Saclay which was recently inaugurated and is planned to
soon become the largest European site for brain imaging studies. NeuroSpin will
host up to 150 research scientists and engineers from CEA and INSERM with a
large number of visiting groups. The core research staff of NeuroSpin has
developed a long history of neuro-imaging research on method and instrumentation
development (notably Position Emission Tomography (PET) and fMRI). In addition
to the Elekta Neuromag MEG system, NeuroSpin will host four cutting-edge
Magnetic Resonance Imaging (MRI) systems entirely dedicated to neuro-imaging
research projects.

“Our research group is interested to use a conventional MEG system as a
necessary complement for MRI systems, which will contribute to the creation of a
center of expertise in medical and cognitive research using MEG and MRI
approaches”, says Professor Stanislas Dehaene, Director of NeuroSpin's Cognitive
NeuroImaging unit.

CEA and Elekta have previously been collaborating through the European
Commission Framework Program on sensor optimization and noise sensitivity for
neuro-imaging applications. “This continued and enlarged cooperation between
Elekta, CEA and INSERM is of great importance for the development of MEG
technology”, says Dr. Claude Fermon, of the nanomagnetism group in the Service
de Physique de l'Etat Condensé, CEA.

For Elekta, the collaboration with CEA and INSERM is an important opportunity to
bring the MEG technology to a whole new level. “We see this as a major
opportunity to work with Europe's top scientists in this field, enabling us to
get further ahead of the competing MEG systems on the market”, says Olof Sandén,
Executive Vice President Europe at Elekta.

Elekta Neuromag®

Elekta Neuromag 306 MEG channels sensor array has higher density than any other
system on the market and thus covers the brain better with a better
representation of brain activity then any other MEG system. With the industry's
lowest noise to signal ratio, meaning that more useful information is acquired,
and thus also the highest yield of information per sample.

The unique design of the sensors combined with advanced software makes it
possible to gain data with unsurpassed detail even from the deepest realms of
the brain. The system also has the highest available immunity to magnetic
interference, either patient-related or external. Elekta Neuromag has also the
lowest operational costs, with the longest liquid helium refill interval. Elekta
Neuromag is technically one of the most sophisticated MEG/EEG devices available
on the market today.







******

For further information, please contact:

Clinical or scientific inquiries: 

Michael Enwall:
Director, MEG Product Marketing Europe & AFLAME
Tel: +46 8 587 25 448, e-mail: michael.enwall@elekta.com

Gordon Haid
Director of Sales, North America, Functional Mapping Business Unit
Tel: +1-604-395-5339, e-mail: gordon.haid@elekta.com

Investor inquiries:

Peter Ejemyr, Group VP Corporate Communications.
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com  

About Elekta

Elekta is an international medical technology group, providing oncologists,
radiation therapists, neurosurgeons and many other medical specialists with
state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and
information systems as well as services for improved cancer care and management
of brain disorders. 

Elekta's systems and solutions are used in over 4,500 hospitals around the
world. Clinical and information management solutions include, among others,
Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta
Axesse™ and Elekta Synergy® for stereotactic and image guided radiation therapy
and radiosurgery as well as the MOSAIQ™ suite of software for image-enabled EMR
and efficient management of clinical and patient data.

With over 2,000 employees globally, the corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. More information about Elekta can be found at www.elekta.com.